Entries by Max

Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide

/in /by

A recent study, published on Nature, in metastatic castration‑resistant prostate cancer (mCRPC) shows that a simple blood test can reveal important information about how the tumor is reprogramming its metabolism and how it responds to enzalutamide, a common androgen‑receptor‑targeting drug. Researchers analyzed the entire circulating “lipidome” (the full panel of fats and related molecules in […]

Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing

/in /by

A new preclinical study shows how a simple tissue sample can be turned into a powerful tool for understanding and treating advanced prostate cancer. Researchers have developed a method to grow patient‑derived organoids from prostate tissue fragments removed during routine transurethral resection of the prostate, or TUR‑P, a common procedure often done for urinary symptoms. […]

Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial

/in , , /by

A new phase 2 EQUIP trial is comparing two different ways of delivering androgen‑suppressive hormone therapy in men with newly diagnosed or recurrent metastatic hormone‑sensitive prostate cancer, focusing on whether transdermal estrogen patches can improve quality of life compared with standard luteinizing hormone‑releasing hormone (LHRH) analogues. The study is designed around two randomized cohorts, each […]

GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer

/in , , /by

A new investigational agent code‑named GLR2037 has entered early clinical development as a first‑in‑human phase 1 study in patients with advanced prostate cancer, representing a significant step in the evolution of androgen receptor–directed therapies. GLR2037 is an androgen receptor (AR)–targeting proteolysis‑targeting chimera (PROTAC), designed not merely to inhibit the AR but to promote its ubiquitin‑proteasome–mediated […]

Durable PSA Control After Testosterone Recovery in High‑Risk Biochemical Recurrent Prostate Cancer

/in /by

A recent post hoc analysis of the phase 3 EMBARK trial in high‑risk biochemical recurrent prostate cancer has generated considerable interest because it suggests that durable, long‑term PSA control can occur even after testosterone has fully recovered to eugonadal levels, challenging the conventional assumption that hormonal suppression must be continuous to maintain remission. The analysis […]

Amino Acid Mix Supercharges Lipid Nanoparticle Delivery for mRNA and CRISPR Therapies

/in , /by

Scientists have discovered that a simple mix of three amino acids can greatly improve how well lipid‑nanoparticle (LNP)–based therapies work in the body. These LNPs are tiny fat‑like packages used to carry mRNA or CRISPR components into cells, and they are already at the heart of new vaccines and gene‑editing treatments. The new finding suggests […]

HITMAN-PC Phase 1 Results: Hydroxychloroquine + SUBA-Itraconazole Stabilizes Biochemical Prostate Cancer Relapse

/in , , /by

The HITMAN-PC trial represents a targeted metabolic approach to managing biochemical relapse in prostate cancer, combining hydroxychloroquine (HCQ) and SUBA-itraconazole (SI) to disrupt lysosomal function and cholesterol trafficking in hormone-sensitive disease. In this phase 1 dose-escalation study, 11 men (median age 73, baseline PSA 4.4 ng/mL, PSA doubling time 5.3 months) received fixed SI at […]

Newsletter 10/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Another week full of interesting and promising clinical trials! The approaches are multiplying, and immunotherapies are advancing even for prostate cancer, which is beginning to respond. Stay strong and fight on! As usual, we also have a podcast if […]

P‑PSMA‑101 CAR‑T Therapy in Advanced Prostate Cancer: Early Results from a Phase 1 Trial

/in , , /by

P‑PSMA‑101 is an experimental CAR‑T cell therapy being tested in men with metastatic castration‑resistant prostate cancer (mCRPC) who have already received multiple standard treatments (up to 10 before enrollment). In the phase 1 trial, 33 men with heavily pretreated mCRPC received P‑PSMA‑101, an autologous PSMA‑targeted CAR‑T product enriched in stem‑cell‑like memory T cells and engineered […]